Ting Xu
CEO Alphamab Oncology
Seminars
Wednesday 5th November 2025
Showcasing Development of Dual Payload Bispecific ADCs to Deliver Payload Combinations With Enhanced Tumor Targeting
12:00 pm
- Showcasing preclinical development of JSKN021, a bispecific dual payload ADC in IND-enabling studies
- Assessing development andmdesign of other early stagembispecific ADC and dual payload conjugates
- Looking to the future: Evaluating the potential of dual payload ADCs with enhanced tumor targeting properties
